FDA
-
-
-
-
-
-
-
Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases
-
-
-
-
-
-
-
Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress
-
-
-
-
-
-
-
ARUNA BIO APPOINTS STEPHEN FROM AS CHIEF EXECUTIVE OFFICER
-
-
-
-
-
-
-
Kiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients with Dry Eye Disease
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

